SEC Form 13F
| Report period | 2024-09-30 |
|---|---|
| Publicly available | 2024-11-15 |
| Reported value | $57,005,443 |
| Positions | 9 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| SPDR S&P 500 ETF TR | SPY | TR UNIT | $46,990,370 | 81,899 |
| GSK PLC | GSK | SPONSORED ADR | $4,059,384 | 99,300 |
| GSK PLC | GSK | SPONSORED ADR | $2,068,528 | 50,600 |
| ARGENX SE | ARGX | SPONSORED ADR | $1,056,514 | 1,949 |
| RIO TINTO PLC | RIO | SPONSORED ADR | $796,036 | 11,185 |
| ARGENX SE | ARGX | SPONSORED ADR | $704,704 | 1,300 |
| FRONTLINE PLC | FRO | COM | $541,545 | 23,700 |
| ARCELORMITTAL SA LUXEMBOURG | MT | NY REGISTRY SH | $517,322 | 19,700 |
| ARGENX SE | ARGX | SPONSORED ADR | $271,040 | 500 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.